Antidepressant-like effects of a novel pentapeptide, nemifitide, in an animal model of depression

Psychopharmacology

Volumn 175, Issue 3, 2004, Pages 303-309

  Overstreet, David H ^a   Hlavka, Joseph ^b   Feighner, John P ^b   Nicolau, Gabriela ^b   Freed, Jeffrey S ^b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b Tetragenex Pharmaceuticals Inc   (United States)

Author keywords

Desipramine; Flinders Sensitive Line rat model of depression; Fluoxetine; Forced swim test; Nemifitide

Indexed keywords

ANTIDEPRESSANT AGENT; DESIPRAMINE; FLUOXETINE; NETAMIFTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DEPRESSION; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; EXPERIMENTAL RAT; FLINDERS SENSITIVE LINE RAT; FORCED SWIMMING TEST; LONG TERM CARE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SWIMMING;

ANIMALS; ANTIDEPRESSIVE AGENTS; DEPRESSION; DESIPRAMINE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUOXETINE; MALE; MOTOR ACTIVITY; OLIGOPEPTIDES; RATS; SELECTION (GENETICS); SPECIES SPECIFICITY;

EID: 5444242555     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-004-1815-9     Document Type: Article

References (46)

1. 1A antagonists. Trends Neurol Sci 19:378-383
2. Blier P (2003) The pharmacology of putative early onset antidepressant strategies. Eur Neuropsychopharmacol 13:57-66
3. Borsini F, Cesana R (2001) Mechanism of action of flibanserin in the learned helpless paradigm in rats. Eur J Pharmacol 433:81-89
4. Borsini F, Meli A (1988) Is the forced swim test a suitable model for revealing antidepressant activity? Psychopharmacology 94:147-160
5. Bushnell PJ, Levin ED, Overstreet DH (1995) Spatial working and reference memory in rats bred for autonomic sensitivity to cholinergic stimulation; acquisition, accuracy, speed, and effects of cholinergic drugs. Neurobiol Learn Mem 63:116-132
6. Cervo L, Grignaschi, Rossi C, Samanin S (1991) Role of serotonergic neurons in the effects of sertraline in rats in the forced swimming test. Eur J Pharmacol 196:217-222
7. Ehrensing RH, Kastin AJ, Wurzlow GF, Michell GF, Mebane AH (1994) Improvement in major depression after low subcutaneous doses of MIF-1. J Affect Disord 31:227-233
8. Feighner JP (2003) Clinical and preclinical overview of nemifitide (INN 00835), a novel pentapeptide antidepressant. Presentation at the Pasteur Institute Congress, Paris
9. Feighner JP, Ehrensing RH, Kastin AJ, Leonard BE, Sverdlov L, Nicolau G, Patel A, Hlavka JJ, Abajian H, Noble JF (2000a) A double-blind, placebo-controlled, efficacy, safety, and pharmacokinetic study of INN 00835, a novel antidepressant peptide, in treatment of major depression. J Affect Disord 61:119-126
10. Feighner JP, Sverdlov L, Nicolau G, Noble JF (2000b) Cluster analysis of clinical data to identify subtypes within a study population following treatment with a new pentapeptide antidepressant. Int J Neuropsychopharmacol 3:237-242
11. Feighner JP, Ehrensing RH, Kastin AJ, Patel A, Sverdlov L, Hlavka J, Abajian HB, Noble JF, Nicolau G (2001) Double-blind, placebo-controlled study of INN 00835 (nemifitide) in the treatment of outpatients with major depression. Int Clin Psychopharmacol 16:345-352
12. Feighner JP, Nicolau G, Abajian H, Marricco NC, Morrison J, Sverdlov L, Hlavka J, Tonelli G Jr, DiSpirito C, Faria G (2002) Clinical pharmacokinetic studies with INN 00835 (nemifitide), a novel pentapeptide antidepressant. Biopharmaceut Drug Dispos 23:33-39
13. Hiemke C, Hartter S (2000) Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol Ther 85:11-28
14. Hlavka JJ, Abajian HB, Noble JF (1996) Chemistry and pharmacology of novel antidepressant peptide. Pharm Res 13:143
15. Hlavka JJ, Feighner JP, Abajian H, Nicolau G, Morrison J, Sverdlov L (2002) Chemistry, pharmacology and clinical studies of nemifitide, a novel antidepressant peptide. Drugs Fut (Suppl A):273
16. Janowsky DS, Overstreet DH, Nurnberger JI Jr (1994) Is cholinergic sensitivity a genetic marker for the affective disorders? Am J Med Genet (Neuropsychiatr Genet) 54:335-344
17. Kastin AJ, Scollan EL, Ehrensing RH (1978) Enkephalin and other peptides reduce passiveness. Pharmacol Biochem Behav 9L:515-519
18. Kastin AJ, Honour LC, Coy DH (1981) Effects of MIF-1 and three related peptides on reserpine-induced hypothermia in mice. Pharmacol Biochem Behav 15:983-985
19. Kelly JP, Leonard BE (1994) The effects of tianeptine and sertraline in three animal models of depression. Neuropharmacology 33:1011-1016
20. Kelly JP, Wrynn AS, Leonard BE (1997) The olfactory bulbectomized rat as a model of depression: an update. Pharmacol Ther 74:299-316
21. Kelly J, Harkin A, Nicolau G, Feighner JP, Leonard BE (2002) A preclinical investigation of the mechanism of action of Nemifitide: a possible role for serotonin? Int J Neuropsychopharmacol 5(Suppl 1):S97
22. Nicolau G, Feighner JP, Reimer M, Li A, Hu Z, Hlavka J (2002) Metabolism of the antidepressant nemifitide and its potential for drug interactions. Int J Neuropsychopharmacol 5 (Suppl 1): S204
23. Nicolau G, Feighner JP, Silber P, Chen G, Abajian H, Bathala M (2003) Metabolism phenotype and in vitro drug-drug interaction studies with Nemifitide, a novel pentapeptide antidepressant. Eur Neuropsychopharmacol 13 (Suppl 4):S194
24. Overstreet DH (1986) Selective breeding for increased cholinergic function: development of a new animal model of depression. Biol Psychiatry 21:49-58
25. Overstreet DH (1993) The Flinders Sensitive Line rats: a genetic animal model of depression. Neurosci Biobehav Rev 17:51-68
26. Overstreet DH (2002) Behavioral characteristics of rat lines selected for differential hypothermic responses to cholinergic or serotonergic agonists. Behav Genet 32:335-348
27. Overstreet DH, Russell RW (1982) Selective breeding for sensitivity to DFP. Effects of cholinergic agonists and antagonists. Psychopharmacology 78:150-154
28. Overstreet DH, Dilsaver SC, Janowsky DS, Rezvani AH (1990) Effects of bright light on responsiveness to a muscarinic agonist in rats selectively bred for endogenously increased cholinergic function. Psychiatry Res 33:149-150
29. Overstreet DH, Rezvani AH, Pucilowski O, Gause L, Janowsky DS (1994) Rapid selection for serotonin-1A sensitivity in rats. Psychiatr Genet 4:57-62
30. Overstreet DH, Pucilowski O, Rezvani AH, Janowsky DS (1995) Administration of antidepressants, diazepam and psychomotor stimulants further confirms the utility of Flinders Sensitive Line rats as an animal model of depression. Psychopharmacology 121:27-37
31. Overstreet DH, Rezvani AH, Knapp DJ, Crews FT, Janowsky DS (1996) Further selection of rat lines differing in 5-HT-1A receptor sensitivity: behavioral and functional correlates. Psychiatr Genet 6:107-117
32. Overstreet DH, Pucilowski O, Rettori M-C, Delagrange P, Guardiola-Lemaitre B (1998) Anti-immobility effects of a melatonin receptor agonist, but not antagonist, in a genetic animal model of depression. NeuroReport 9:249-253
33. Pignatiello MF, Olson GA, Kastin AJ, Ehrensing RH, McLean JH, Olson RD (1989) MIF-1 is active in a chronic stress animal model of depression. Pharmacol Biochem Behav 32:737-742
34. Plenge P, Mellerup ET (2003) Pindolol and the acceleration of the antidepressant response. J Affect Disord 75:285-289
35. Porsolt RD, Anton G, Blavet N, Jalfre M (1977) Behavioral despair in rats: a new model sensitive to antidepressant treatment. Eur J Pharmacol 47:379-391
36. Pucilowski O, Overstreet DH (1993) Effect of chronic antidepressant treatment on responses to apomorphine in selectively bred rat strains. Pharmacol Biochem Behav 32:471-475
37. Pucilowski O, Overstreet DH, Rezvani AH, Janowsky DS (1993) Chronic mild stress-induced anhedonia: greater effect in genetic rat model of depression. Physiol Behav 54:1215-1220
38. Raghavendra V, Kaur G, Kulkarni SK (2000) Antidepressant action of melatonin in chronic forced swim-induced behavioral despair in mice, role of peripheral benzodiazepine receptor modulation. Eur Neuropsychopharmacol 10:473-481
39. Sanchez C, Hyttel J (1999) Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cell Mol Neurobiol 19:467-489
40. Schiller GD, Pucilowsky O, Overstreet DH (1992) Immobility-reducing effect of antidepressants in a genetic animal model of depression. Brain Res Bull 28:821-823
41. Shiromani PJ, Overstreet DH, Levy D, Goodrich CA, Campbell SS, Gillin JC (1988) Increased REM sleep in rats selectively bred for cholinergic hyperactivity. Neuropsychopharmacology 1:127-133
42. Shiromani PJ, Overstreet DH, Lucero S (1990) Failure of dietary lithium to alter immobility in animal model of depression. Lithium 1:241-244
43. van der Velde CD (1983) Rapid clinical effectiveness of MIF-1 in the treatment of major depressive illness. Peptides 4:297-300
44. Willner P (1997) Validity, reliability and utility of the chronic mild stress model of depression: a 10-year review and evaluation. Psychopharmacology 134:129-139
45. Willner P, Muscat R, Papp M (1993) Chronic mild stress-induced anhedonia: a realistic animal model of depression. Neurosci Biobehav Rev 16:525-534
46. Yadid G, Zangen A, Dmitrochenko A, Overstreet DH, Zohar J (2000) Screening for new antidepressants with fast onset and long-lasting action. Drug Dev Res 50:392-399